We conducted a study to examine cochlear activity in women with a naturally occurring menstrual cycle by measuring transient otoacoustic emissions (rOAEs) and distortion-product otoacoustic emissions (DPOAEs). Our studypopulation wasmade up of11 womenaged20 to40 years (mean: 35.6) who were not taking a contraceptive medication orhormonetherapy. Measurements ofrOAEs and DPOAEs were made duringboth thefollicular phase and the lutealphaseof the menstrualcycle. Wefound no statistically significant difference in any of the rOAE amplitude values between the twophases. Althougha sharp decrease at the 0.75kHzfrequency wasseenin DPOAEs during both phases, none of the amplitude values in the testedfrequencies were significantly different between the twophases. The absence ofrOAE andDPOAEamplitude changes suggests that it isunnecessary totakeintoaccount the phase of the menstrual cycle when interpreting the results of otoacoustic emissions testing.
Introduction
The menstrual cycle is divided into three phases: follicular, ovulatory, and luteal. The follicular phase starts with menstrual bleeding and lasts about 15 days. After ovulation, the luteal phase begins; it lasts about 13 to 15 days and ends with the next onset of menses. In the luteal phase, progesterone levels increase and levels of luteinizing hormone/follicle-stimulating hormone (LH/ FSH) and estrogen decrease. High progesterone levels may increase sodium, chloride, and water reabsorption. The menstrual cycle ends when progesterone and LH/ FSH levels are at a minimum.
Homeostasis and the biochemical status of inner ear fluids are essential for balance and for hearing. Women with naturally occurring menstrual cycles may experience fluctuations in auditory and labyrinthine functions during certain times in their menstrual cycle. 1 The physiologic basis ofthis relationship isunclear. Menstrual cycle variations in sodium and water absorption/reabsorption and hormonal influences on cochlear blood flow affect the active mechanism of the cochlea.P It has been proposed that the frequencies ofotoacoustic emissions (OAEs) may be used to assess such variations during the different phases of the cycle. Therefore, we conducted a study to examine the hair cell activity in women during a normal menstrual cycle. Our goal was to ascertain the effects of hormone variations in cycle phases by means of measuring transient otoacoustic emissions (TOAEs) and distortion-product otoacoustic emissions (DPOAEs).
Subjects and methods
Our study population was made up of 11 women aged 20 to 40 years (mean: 35.6) who were not taking any contraceptive agents or hormone therapy. All were interviewed to obtain an otologic history and information about their use of medications and their menstrual cycles, The history and findings on routine ENT examination (otoscopy) and pure-tone audiometry were within normal limits, and there were no impediments to OAE testing.
Once the absence of auditory pathology was confirmed, the assessment of TOAEs and DPOAEs was The following treatment-rel ated adverse eventswere each reported in a single patient: tympanostomy tube blockage; ear pruritus; tinnitus; oral moniliasis; crying; dizziness; and erythema. Acute Ot itis Exlema: The following treatment-related adverse events occurred in 0.4%or more of thepatientswithIntact tympanicmembranes.
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Discussion
OAEs are the sounds generated by contractions of the outer hair cells following the presentation of a sound were considered present when the difference between amplitude and noise was greater than 6 dB.
Multivariate data analysis was performed with the Statistical Package for the Social Sciences software (v. 13.0; SPSS; Chicago) to assess the effect of the phase of the menstrual cycle on OAEs.
The study protocol was approved by the Research Ethics Committee of the I Gaziosmanpasa Univer-1 40 sity Faculty of Medicine, and written informed 1 30 1 ------:;;------------::::::;:::;115;;::=-----consent was obtained from all patients. 20 t----------------------------
Results
There was no statistically significant difference in mean TOAE amplitudes at 1.0, 1.5, 2.0, 3.0, and 4.0 kHz between the follicular phase (figure 1) and the luteal phase of difficulty of surgery. However, the ability to predict the difficulty of surgery before going to the operating room with an objective measurement like pure-tone audiometry would be more helpful in teaching hospital settings, where residents are being trained for these operations and are allowed to operate on some patients. More studies that measure footplate thickness as a quantitative parameter and the relationship between footplate thickness and the histologic pattern of otosclerotic lesions are needed.
hearing, normal-cyclingwomen. 7Theyfound no systematic amplitude changes and no correlation with phases of the menstrual cycle, and they concluded that evoked OAEs are unaffected by physiologic changes associated with the menstrual cycle.
Likewise,Arruda and Silvaassessed 21women aged 20 to 35 years who did not take any contraceptive medicine by TOAE and DPOAE testing during the three phases of the menstrual cycle," While the authors noticed a difference between right and left ears (DPOAEs at 1.5 kHz were higher on the right side), they found no statistically significant differences in TOAEs and DPOAEs during any of the phases.
An important factor that limits the usefulness ofspontaneous OAEs is that they occur in only 40 to 50% of normal-hearing individuals.4-6 So while the presence of spontaneous OAEs is usually considered a sign of good cochlear health, their absence is not necessarily a sign of audiologic pathology. Therefore, we did not evaluate spontaneous OAEs in our subjects.
None of our subjects used anovulatory contraceptives during the study, nor did they experience other hormonal changes such as amenorrhea or menopause. We excluded such women because these factors can affect the dynamics of OAE frequencies. Our finding that there was no significant correlation between TOAEs and DPOAEs and the phases of the menstrual cycle suggest that it is unnecessary to take the phase of the menstrual cycle into account when interpreting OAE test results.
